Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

ECyd evaluated for mechanism of action, potential clinical activity

Feb. 10, 1999

Nonpeptide GnRH antagonists claimed by Merck & Co.

Feb. 9, 1999

New photoactive agents in development at QLT and U. of British Columbia

Feb. 9, 1999

Hughes Institute enters licensing agreement for anticancer drug development

Feb. 9, 1999

Boston Life Sciences identifies a second antiangiogenic molecule

Feb. 8, 1999

Orphan Medical's Busulfex Injection approved in U.S.

Feb. 8, 1999

Lorus Therapeutics announces preclinical data on anticancer compound

Feb. 8, 1999

Aronex's NDA for Atragen accepted for review

Feb. 5, 1999

Vitaxin proceeds to phase II

Feb. 5, 1999

First phase I clinical trials commence with NX-211

Feb. 4, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 8, 2026.
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.